{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:20:27Z","timestamp":1792783227018,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Proveris Scientific Corporation"},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s11095-025-03860-0","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T15:47:40Z","timestamp":1745855260000},"page":"639-650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["An In Vitro Dissolution Method for Inhaled Drugs Depositing in the Tracheobronchial Lung Region"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8623-004X","authenticated-orcid":false,"given":"Alexander","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3951-9339","authenticated-orcid":false,"given":"Scott","family":"Tavernini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dino J.","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren H.","family":"Finlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"3860_CR1","doi-asserted-by":"crossref","unstructured":"Finlay WH. The mechanics of inhaled pharmaceutical aerosols : an introduction. 2nd ed. Academic Press; 2019.","DOI":"10.1016\/B978-0-08-102749-3.00001-4"},{"issue":"1","key":"3860_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nrd2153","volume":"6","author":"JS Patton","year":"2007","unstructured":"Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discovery. 2007;6(1):67\u201374. https:\/\/doi.org\/10.1038\/nrd2153.","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"3860_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/jamp.2021.29033.am","volume":"34","author":"AR Martin","year":"2020","unstructured":"Martin AR. Regional deposition: targeting. J Aerosol Med Pulm Drug Deliv. 2020;34(1):1\u201310. https:\/\/doi.org\/10.1089\/jamp.2021.29033.am.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"1","key":"3860_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1021\/acs.molpharmaceut.3c00685","volume":"21","author":"JE Hastedt","year":"2023","unstructured":"Hastedt JE, B\u00e4ckman P, Cabal A, Clark A, Ehrhardt C, Forbes B, et al. iBCS: 3. A biopharmaceutics classification system for orally inhaled drug products. Mol Pharm. 2023;21(1):164\u201372.","journal-title":"Mol Pharm"},{"key":"3860_CR5","doi-asserted-by":"publisher","unstructured":"Forbes B, Richer NH, Buttini F. Dissolution: a critical performance characteristic of inhaled products?. In: Nokhodchi\u00a0A, Martin GP, editors. Pulmonary drug delivery. Chichester (England): John\nWiley & Sons; 2015. https:\/\/doi.org\/10.1002\/9781118799536.ch10","DOI":"10.1002\/9781118799536.ch10"},{"key":"3860_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.26650\/IstanbulJPharm.2023.1005069","volume":"53","author":"B Falade","year":"2023","unstructured":"Falade B, Ehrhardt C. In vitro dissolution testing methods for inhaled drugs. \u0130stanb J Pharm. 2023;53:239\u201350. https:\/\/doi.org\/10.26650\/IstanbulJPharm.2023.1005069.","journal-title":"\u0130stanb J Pharm"},{"issue":"10","key":"3860_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s11095-020-02924-7","volume":"37","author":"CA Ruzycki","year":"2020","unstructured":"Ruzycki CA, Murphy B, Nathoo H, Finlay WH, Martin AR. Combined in vitro-in silico approach to predict deposition and pharmacokinetics of budesonide dry powder inhalers. Pharm Res. 2020;37(10):209. https:\/\/doi.org\/10.1007\/s11095-020-02924-7.","journal-title":"Pharm Res"},{"issue":"3","key":"3860_CR8","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1208\/s12249-012-9822-3","volume":"13","author":"T Riley","year":"2012","unstructured":"Riley T, Christopher D, Arp J, Casazza A, Colombani A, Cooper A, et al. Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs). AAPS PharmSciTech. 2012;13(3):978\u201389. https:\/\/doi.org\/10.1208\/s12249-012-9822-3.","journal-title":"AAPS PharmSciTech"},{"issue":"8","key":"3860_CR9","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3390\/pharmaceutics13081109","volume":"13","author":"E Amini","year":"2021","unstructured":"Amini E, Kurumaddali A, Bhagwat S, Berger SM, Hochhaus G. Optimization of the transwell\u00ae system for assessing the dissolution behavior of orally inhaled drug products through in vitro and in silico approaches. Pharmaceutics. 2021;13(8):1109. https:\/\/doi.org\/10.3390\/pharmaceutics13081109.","journal-title":"Pharmaceutics"},{"issue":"8","key":"3860_CR10","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1021\/acs.molpharmaceut.5b00221","volume":"12","author":"M Rohrschneider","year":"2015","unstructured":"Rohrschneider M, Bhagwat S, Krampe R, Michler V, Breitkreutz J, Hochhaus G. Evaluation of the transwell system for characterization of dissolution behavior of inhalation drugs: effects of membrane and surfactant. Mol Pharm. 2015;12(8):2618\u201324. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00221.","journal-title":"Mol Pharm"},{"issue":"2","key":"3860_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1208\/s12248-020-0422-y","volume":"22","author":"R Price","year":"2020","unstructured":"Price R, Shur J, Ganley W, Farias G, Fotaki N, Conti DS, et al. Development of an aerosol dose collection apparatus for in vitro dissolution measurements of orally inhaled drug products. Aaps j. 2020;22(2):47. https:\/\/doi.org\/10.1208\/s12248-020-0422-y.","journal-title":"Aaps j"},{"issue":"11","key":"3860_CR12","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1021\/acs.molpharmaceut.8b00796","volume":"15","author":"F Franek","year":"2018","unstructured":"Franek F, Fransson R, Th\u00f6rn H, B\u00e4ckman P, Andersson PU, Tehler U. Ranking in vitro dissolution of inhaled micronized drug powders including a candidate drug with two different particle sizes. Mol Pharm. 2018;15(11):5319\u201326. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00796.","journal-title":"Mol Pharm"},{"key":"3860_CR13","unstructured":"Ong HX, Marasini N, Rao L, Duke DJ, Honnery D, Stein S, et al. Do In-vitro dissolution rates differ between beclomethasone dipropionate particles generated from solution-based pMDIs formulated with HFA134a, HFA152a and HFO1234ze(E) propellants? Drug Delivery to the Lungs. Edinburgh, UK 2023;96\u2013100."},{"issue":"2","key":"3860_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.14227\/DT170210P6","volume":"17","author":"Y-J Son","year":"2010","unstructured":"Son Y-J, Horng M, Copley M, McConville J. Optimization of an in vitro dissolution test method for inhalation formulations. Dissolution Technol. 2010;17(2):6\u201313.","journal-title":"Dissolution Technol"},{"issue":"4","key":"3860_CR15","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s11095-022-03242-w","volume":"39","author":"H Wang","year":"2022","unstructured":"Wang H, Ordoubadi M, Connaughton P, Lachacz K, Carrigy N, Tavernini S, et al. Spray dried rugose lipid particle platform for respiratory drug delivery. Pharm Res. 2022;39(4):805\u201323. https:\/\/doi.org\/10.1007\/s11095-022-03242-w.","journal-title":"Pharm Res"},{"issue":"12","key":"3860_CR16","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1007\/s11095-022-03421-9","volume":"39","author":"S Tavernini","year":"2022","unstructured":"Tavernini S, Farina DJ, Martin AR, Finlay WH. Using filters to estimate regional lung deposition with pressurized metered dose inhalers. Pharm Res. 2022;39(12):3371\u201380. https:\/\/doi.org\/10.1007\/s11095-022-03421-9.","journal-title":"Pharm Res"},{"issue":"9","key":"3860_CR17","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s11095-021-03082-0","volume":"38","author":"S Tavernini","year":"2021","unstructured":"Tavernini S, Farina DJ, Martin AR, Finlay WH. Using filters to estimate regional lung deposition with dry powder inhalers. Pharm Res. 2021;38(9):1601\u201313. https:\/\/doi.org\/10.1007\/s11095-021-03082-0.","journal-title":"Pharm Res"},{"key":"3860_CR18","doi-asserted-by":"publisher","unstructured":"Huang A, Tavernini S, Farina DJ, Finlay WH, Martin AR. Investigating drug loading on stainless-steel mesh filters used for estimating regional lung deposition. Drug delivery to the lungs. Edinburgh; 2023. pp. 344\u2013347.\u00a0https:\/\/doi.org\/10.60565\/rt43-7m33","DOI":"10.60565\/rt43-7m33"},{"issue":"3","key":"3860_CR19","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s11095-016-2050-x","volume":"34","author":"J Weers","year":"2017","unstructured":"Weers J, Clark A. The impact of inspiratory flow rate on drug delivery to the lungs with dry powder inhalers. Pharm Res. 2017;34(3):507\u201328. https:\/\/doi.org\/10.1007\/s11095-016-2050-x.","journal-title":"Pharm Res"},{"issue":"2","key":"3860_CR20","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1089\/jamp.2015.1215","volume":"29","author":"RR Delvadia","year":"2016","unstructured":"Delvadia RR, Wei X, Longest PW, Venitz J, Byron PR. In vitro tests for aerosol deposition. IV: Simulating variations in human breath profiles for realistic DPI testing. J Aerosol Med Pulm Drug Deliv. 2016;29(2):196\u2013206. https:\/\/doi.org\/10.1089\/jamp.2015.1215.","journal-title":"J Aerosol Med Pulm Drug Deliv."},{"key":"3860_CR21","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1089\/jamp.2010.0846","volume":"23","author":"PR Byron","year":"2010","unstructured":"Byron PR, Hindle M, Lange CF, Longest PW, McRobbie D, Oldham MJ, et al. In vivo\u2013in vitro correlations: predicting pulmonary drug deposition from pharmaceutical aerosols. J Aerosol Med Pulm Drug Deliv. 2010;23:S59\u201369. https:\/\/doi.org\/10.1089\/jamp.2010.0846.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"6","key":"3860_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1089\/jamp.2019.1531","volume":"32","author":"CA Ruzycki","year":"2019","unstructured":"Ruzycki CA, Martin AR, Finlay WH. An exploration of factors affecting in vitro deposition of pharmaceutical aerosols in the alberta idealized throat. J Aerosol Med Pulm Drug Deliv. 2019;32(6):405\u201317. https:\/\/doi.org\/10.1089\/jamp.2019.1531.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"3860_CR23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.ultsonch.2015.10.022","volume":"29","author":"SV Pereira","year":"2016","unstructured":"Pereira SV, Colombo FB, de Freitas LA. Ultrasound influence on the solubility of solid dispersions prepared for a poorly soluble drug. Ultrason Sonochem. 2016;29:461\u20139. https:\/\/doi.org\/10.1016\/j.ultsonch.2015.10.022.","journal-title":"Ultrason Sonochem"},{"issue":"9","key":"3860_CR24","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1021\/acs.molpharmaceut.2c00177","volume":"19","author":"I van der Zwaan","year":"2022","unstructured":"van der Zwaan I, Franek F, Fransson R, Tehler U, Frenning G. Characterization of membrane-type dissolution profiles of clinically available orally inhaled products using a weibull fit and a mechanistic model. Mol Pharm. 2022;19(9):3114\u201324. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00177.","journal-title":"Mol Pharm"},{"issue":"1","key":"3860_CR25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ijpharm.2013.04.044","volume":"453","author":"J Siepmann","year":"2013","unstructured":"Siepmann J, Siepmann F. Mathematical modeling of drug dissolution. Int J Pharm. 2013;453(1):12\u201324. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.04.044.","journal-title":"Int J Pharm"},{"issue":"2","key":"3860_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/s0928-0987(01)00095-1","volume":"13","author":"P Costa","year":"2001","unstructured":"Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123\u201333. https:\/\/doi.org\/10.1016\/s0928-0987(01)00095-1.","journal-title":"Eur J Pharm Sci"},{"key":"3860_CR27","unstructured":"U.S. Food and Drug Administration. Guidance for Industry: Dissolution Testing of Immediate-Release Solid Oral Dosage Forms. Rockville, MD, USA: Food and Drug Administration: Silver Spring, MD, USA; Center for Drug Evaluation and Research (CDER) 1997."},{"key":"3860_CR28","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on the Investigation of Bioequivalence. European Medicines Agency; 2010."},{"issue":"8","key":"3860_CR29","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s11095-012-0744-2","volume":"29","author":"S May","year":"2012","unstructured":"May S, Jensen B, Wolkenhauer M, Schneider M, Lehr CM. Dissolution techniques for in vitro testing of dry powders for inhalation. Pharm Res. 2012;29(8):2157\u201366. https:\/\/doi.org\/10.1007\/s11095-012-0744-2.","journal-title":"Pharm Res"},{"key":"3860_CR30","unstructured":"US FDA Center for Drug Evaluation and Research. Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Products - Quality Considerations. Guidance for Industry (draft). 2018."},{"issue":"3","key":"3860_CR31","doi-asserted-by":"publisher","first-page":"983","DOI":"10.3390\/pharmaceutics15030983","volume":"15","author":"A Nokhodchi","year":"2023","unstructured":"Nokhodchi A, Chavan S, Ghafourian T. In vitro dissolution and permeability testing of inhalation products: challenges and advances. Pharmaceutics. 2023;15(3):983. https:\/\/doi.org\/10.3390\/pharmaceutics15030983.","journal-title":"Pharmaceutics."},{"issue":"2","key":"3860_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1089\/jamp.2014.1199","volume":"29","author":"CL Leach","year":"2015","unstructured":"Leach CL, Kuehl PJ, Chand R, McDonald JD. Respiratory tract deposition of HFA\u2013Beclomethasone and HFA\u2013Fluticasone in asthmatic patients. J Aerosol Med Pulm Drug Deliv. 2015;29(2):127\u201333. https:\/\/doi.org\/10.1089\/jamp.2014.1199.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"10","key":"3860_CR33","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s11095-024-03776-1","volume":"41","author":"G Farias","year":"2024","unstructured":"Farias G, Ganley WJ, Price R, Conti DS, Mangal S, Bielski E, et al. Microstructural characterization of dry powder inhaler formulations using orthogonal analytical techniques. Pharm Res. 2024;41(10):2015\u201329. https:\/\/doi.org\/10.1007\/s11095-024-03776-1.","journal-title":"Pharm Res"},{"issue":"5","key":"3860_CR34","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1046\/j.0306-5251.2001.01493.x","volume":"52","author":"L Thorsson","year":"2001","unstructured":"Thorsson L, Edsb\u00e4cker S, K\u00e4ll\u00e9n A, L\u00f6fdahl CG. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol. 2001;52(5):529\u201338. https:\/\/doi.org\/10.1046\/j.0306-5251.2001.01493.x.","journal-title":"Br J Clin Pharmacol"},{"key":"3860_CR35","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0954-6111(00)80143-2","volume":"94","author":"A Cripps","year":"2000","unstructured":"Cripps A, Riebe M, Schulze M, Woodhouse R. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med. 2000;94:S3-9.","journal-title":"Respir Med."},{"key":"3860_CR36","first-page":"S29","volume":"94","author":"AB Tonnel","year":"2000","unstructured":"Tonnel AB, Bons J, Legendre M, Prud\u2019Homme A, Bugnas B, Evano-Celli I, et al. Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma French study group. Respir Med. 2000;94:S29-34.","journal-title":"Respir Med"},{"issue":"12","key":"3860_CR37","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.3390\/pharmaceutics14122667","volume":"14","author":"BB Eedara","year":"2022","unstructured":"Eedara BB, Bastola R, Das SC. Dissolution and absorption of inhaled drug particles in the lungs. Pharmaceutics. 2022;14(12):2667. https:\/\/doi.org\/10.3390\/pharmaceutics14122667.","journal-title":"Pharmaceutics"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03860-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-025-03860-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03860-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T12:54:42Z","timestamp":1746536082000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-025-03860-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3860"],"URL":"https:\/\/doi.org\/10.1007\/s11095-025-03860-0","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"13 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patents have been filed on the filter-based apparatus described in this work, which may financially benefit the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}